Evidence map›Paper›PMID 36839767›Full record

ArticlePharmaceutics2023

Development of an Oral Liquid Formulation of Nicardipine Hydrochloride Compounded with Simple Excipients for the Treatment of Pediatric Hypertension.

Marine Cavelier, Henri Gondé, Damien Costa, Fabien Lamoureux, Tony Pereira, Nimrod Buchbinder, Rémi Varin, Charles Hervouët

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Marine CavelierCHU Rouen, Department of Pharmacy, F-76000 Rouen, France.
Henri GondéCHU Rouen, Department of Pharmacy, Normandie University, UNIROUEN, U1234, F-76000 Rouen, France.ORCID 0000-0001-7364-3785
Damien CostaCHU Rouen, Department of Parasitology-Mycology, Normandie University, UNIROUEN, EA7510 ESCAPE, F-76000 Rouen, France.ORCID 0000-0003-3418-2597
Fabien LamoureuxCHU Rouen, Department of Pharmacology, F-76000 Rouen, France.
Tony PereiraCHU Rouen, Department of Pharmacology, F-76000 Rouen, France.ORCID 0000-0002-2737-0314
Nimrod BuchbinderCHU Rouen, Department of Pediatric Oncology and Hematology, F-76000 Rouen, France.
Rémi VarinCHU Rouen, Department of Pharmacy, Normandie University, UNIROUEN, U1234, F-76000 Rouen, France.
Charles HervouëtCHU Rouen, Department of Pharmacy, F-76000 Rouen, France.
Centre Hospitalier Universitaire de Rouen · FRNormandie Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicardipine hydrochloride is an anti-hypertensive drug that is used off-label to treat hypertension in children. A previous oral formulation of nicardipine hydrochloride was developed using a commercial vehicle as an excipient. However, ready-to-use vehicles are prone to supply shortages, and their composition may undergo substantial modifications. The aim of this study was to propose a new oral formulation of nicardipine hydrochloride 2 mg/mL using simple excipients. The formulation included hydroxypropylmethylcellulose, simple syrup, polysorbate 80, sodium saccharin, citrate buffer, strawberry flavor and 0.2% potassium sorbate. The uniformity of content was maintained before and after agitation. Nicardipine hydrochloride concentration assessed by HPLC-MS/MS remained above 90% for 365 days before opening and for 28 days after opening. pH and osmolality were maintained throughout the study, and no microbial contamination was observed. The uniformity of mass of the delivered doses was evaluated using four different devices. A new oral formulation of nicardipine hydrochloride 2 mg/mL was developed using simple and safe excipients. Pharmacological and clinical parameters remain to be assessed and compared with those of the previous formulation.

Indexed as

compoundinghypertensionnicardipine hydrochlorideoral solutionpediatric formulationstability

Identifiers

PMID36839767
PMCPMC9963445
OpenAlexW4318479935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.